10.25% -0.975

Replimune Group Inc (REPL)

Replimune Group Inc Borsa (REPL) Ultime notizie

Replimune Group Inc (REPL)

Replimune Group Inc Borsa (REPL) Ultime notizie

Chief Medical Officer Xynos Konstantinos sold 15881 shares of Replimune Group Inc [REPL] – Knox Daily - Knox Daily

Replimune secures $100 million for cancer therapy scale-u By Investing.com - Investing.com Canada

Replimune Group (NASDAQ:REPL) Shares Gap Up to $8.82 - MarketBeat

Replimune secures $100 million for cancer therapy scale-u By Investing.com - Investing.com

Replimune Group Shares Rise 8% After $100M Private Placement Financing - MarketWatch

Replimune Group Inc, (REPL)’s financial ratios: A comprehensive overview - The Dwinnex

Replimune Group (NASDAQ:REPL) Shares Gap Down After Insider Selling - Defense World

Replimune Group (NASDAQ:REPL) Shares Gap Down on Insider Selling - MarketBeat

A new trading data show Replimune Group Inc (REPL) is showing positive returns. – Sete News - SETE News

Replimune Group Inc (REPL) receives an Overweight rating from Piper Sandler – Knox Daily - Knox Daily

Replimune Group, Inc. (NASDAQ:REPL) Insider Konstantinos Xynos Sells 15881 Shares of Stock - Defense World

Replimune Group (NASDAQ:REPL) Stock Price Up 4.1% After Analyst Upgrade - Defense World

Replimune Group, Inc. (NASDAQ:REPL) Insider Sells $119,107.50 in Stock - MarketBeat

Replimune group's chief medical officer sells shares worth over $119k - Investing.com India

Replimune group's chief medical officer sells shares worth over $119k By Investing.com - Investing.com

Behind Replimune Group Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle

Replimune Group (NASDAQ:REPL) Shares Up 4.1% Following Analyst Upgrade - MarketBeat

Replimune Group Inc (REPL) stock on the rise: An overview - US Post News

Replimune Group (NASDAQ:REPL) Given New $17.00 Price Target at Barclays - Defense World

Rafferty Asset Management LLC Acquires 276,596 Shares of Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Replimune Group (NASDAQ:REPL) Price Target Raised to $17.00 at HC Wainwright - Defense World

Replimune Group Inc [NASDAQ: REPL] Sees Increase in Stock Value – Knox Daily - Knox Daily

BMO holds Replimune stock on positive trial momentum - Investing.com India

Replimune (REPL) Shares Surge Following Positive Trial Results - Catching News

Replimune Group (NASDAQ:REPL) PT Raised to $17.00 at Barclays - MarketBeat

Replimune (REPL) Shares Surge Following Positive Trial Results – Catching News - Catching News

Replimune (REPL) Gains on Positive Data From Melanoma Study - Zacks Investment Research

Replimune (REPL) Gains on Positive Data From Melanoma Study

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Replimune Group Inc (REPL)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News

Replimune Group (NASDAQ:REPL) Receives Outperform Rating from Wedbush - Defense World

Replimune Group (NASDAQ:REPL) Stock Rating Reaffirmed by Wedbush - MarketBeat

Replimune ignites its stock with phase I data in melanoma - BioWorld Online

Replimune ignites its stock with phase I data in melanoma - BioWorld Online

12 Health Care Stocks Moving In Thursday's Intraday Session - Akso Health Group (NASDAQ:AHG), Aethlon Med - Benzinga

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Yahoo Finance Australia

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? By Benzinga - Investing.com UK

Replimune up 30% on results for RP1 combo in melanoma (NASDAQ:REPL) - Seeking Alpha

Replimune ignites its stock with phase I/II data in melanoma - BioWorld Online

Replimune reports RP1 trial results in melanoma therapy - Investing.com India

Replimune reports RP1 trial results in melanoma therapy By Investing.com - Investing.com

Replimune reports RP1 trial results in melanoma therapy By Investing.com - Investing.com Nigeria

Replimune Group Shares Rally on Skin Cancer Study Data - MarketWatch

J.M. Smucker Posts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks ... - Benzinga

Replimune Group's IGNYTE Trial Shows Promising Melanoma Outcomes - TipRanks.com - TipRanks

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday? - Yahoo Finance

Replimune Group Inc (REPL) Stock: A Year of Market Movement, Down and Up - The InvestChronicle

Barclays maintains Overweight on Replimune shares, target steady By Investing.com - Investing.com

Examining the Potential Price Growth of Replimune Group Inc (REPL) – Knox Daily - Knox Daily

Simile a REPL